Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial-Reference-Cited by-同舟云学术

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

Published:2015-04-06 Issue:1 Volume:17 Page:
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Kremer Joel M,Kivitz Alan J,Simon-Campos Jesus A,Nasonov Evgeny L,Tony Hans-Peter,Lee Soo-Kon,Vlahos Bonnie,Hammond Constance,Bukowski Jack,Li Huihua,Schulman Seth L,Raber Susan,Zuckerman Andrea,Isaacs John D

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1186/s13075-015-0612-7.pdf

Reference31 articles.

1. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–60.

2. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.

3. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253–61.

4. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–70.

5. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis;PLOS ONE;2024-07-31

2. Chronic Kidney Disease in Inflammatory Bowel Disease: a Systematic Review and Meta-analysis;Journal of Crohn's and Colitis;2024-04-08

3. Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics;MedComm – Oncology;2024-03

4. Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis;Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice;2024-02-28

5. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story;Annals of the Rheumatic Diseases;2023-11-03